<DOC>
	<DOCNO>NCT01810120</DOCNO>
	<brief_summary>Allocation : Non-Randomized Endpoint Classification : Safety/Feasibility Intervention Model : Single Group Assignment Masking : Open Label Primary Purpose : Treatment Study ass feasibility safety infusion T cell receptor ( TCR ) alfa beta deplete graft pediatric patient affect malignant non-malignant hematological disorder receive Hematopoietic stem cell transplantation ( HSCT ) Human leukocyte antigen ( HLA ) partially match family donor .</brief_summary>
	<brief_title>Trial Assess Efficacy TCR Alfa Beta Depleted Graft Pediatric Affected ALL AML Receiving HSCT</brief_title>
	<detailed_description>In study hypothesis transplantation Peripheral blood stem cell ( PBSC ) selectively deplete TCR alfa beta T lymphocytes would offer advantage use positively select CD34+ stem cell presence non-stem ancillary cell ( particular Natural killer ( NK ) alfa beta T cell ) might potential positive effect outcome transplant . The clinical relevance NK-cell alloreactivity demonstrate adult patient affect Acute myeloid leukemia ( AML ) give T-cell deplete HSCT HLA-disparate relative subgroup patient particularly low risk leukemia relapse . These patient belong group transplant donor NK cell alloreactive towards recipient target i.e . patient cell express HLA-class I alleles share inhibit allelic determinant recognize Killer immunoglobulin-like receptor ( KIR ) donor NK cell . The emergence concept NK-cell alloreactivity represent sort revolution field Haplo-identical hematopoietic stem cell translantation ( haplo-HSCT ) , presence alloreactive NK cell show positively affect outcome transplantation adult display Graft versus leukemia ( GvL ) effect compensate lack T-specific anti-tumor effect . The purpose study evaluate feasibility safety selective infusion TCR alfa beta T cell deplete graft pediatric patient affect malignant non malignant hematological disorder receive HSCT partially match family donor . This study provide new data feasibility safety use TCR alfa beta T cell deplete graft instead fully T cell deplete graft improve outcome patient receive haplo-HSCT treatment hematological disorder .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Patients age â‰¥ 3 month &lt; 21 year Patients diagnose malignant hemopathies ( Acute Lymphoblastic leukemia ( ALL ) , Acute Myeloid Leukemia ( AML ) , NonHodgkin Lymphoma ( NHL ) ) complete morphological remission Myelodysplastic Syndromes ( MDS ) , Solid Tumors non malignant hematological disorder ( SCID , Acquired Congenital Aplastic Anemia , Primary Immunodeficiencies , Lifethreatening Cytopenia ) eligible allogeneic transplantation lack relate unrelated HLAmatched donor Patients display HLApartially match family donor Lansky/Karnofsky score &gt; 40 , WHO &gt; 4 Signed write informed consent Grade &gt; II acute GvHD chronic extensive GvHD time inclusion Patient receive immunosuppressive treatment GvHD treatment time inclusion Dysfunction liver ( ALT/AST &gt; 5 time normal value , bilirubin &gt; 3 time normal value ) , renal function ( creatinine clearance &lt; 30 ml / min ) Severe cardiovascular disease ( arrhythmias require chronic treatment , congestive heart failure leave ventricular ejection fraction &lt; 40 % ) Current active infectious disease ( include positive HIV serology viral RNA ) Serious concurrent uncontrolled medical disorder Pregnant breast feed female patient Lack parent ' informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Hematologic</keyword>
	<keyword>Malignant</keyword>
	<keyword>Non-Malignant</keyword>
	<keyword>Allogeneic</keyword>
	<keyword>Transplant</keyword>
	<keyword>Non-Hodgkin Lymphoma</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Acute lymphoblastic leukemia</keyword>
	<keyword>Acute Myeloid leukemia</keyword>
	<keyword>Myelodysplastic Syndromes</keyword>
	<keyword>T cell receptor alfa beta</keyword>
</DOC>